Showing posts with label Marie Ennis-O’Connor. Show all posts
Showing posts with label Marie Ennis-O’Connor. Show all posts

Wednesday, January 30, 2019

Research News - Jan 2019

A friend, social media guru and breast cancer survivor, Marie Ennis-O'Connor,  writes a weekly post in which she shares blog posts she found interesting from the week before.  In 15 Smart Ways to Drive More Traffic To Your Blog in Medium ( https://medium.com/@JBBC/15-effective-ways-to-drive-more-traffic-to-your-blog-75e1943b88f4) to recommended creating "a weekly round-up post on your blog".  I've been meaning to do this for a while but had trouble deciding what I wanted to share. Should it be journal articles or survivor stories or new resources or events? Earlier this week I decided to concentrate on research news and went to work creating a graphic I could use for these repeating posts.


On the last Wednesday of the month I will provide links to articles on ovarian cancer research and treatments I read during that month.

Here are some interesting articles published in January:

"The recent addition of targeted therapies – anti-angiogenic agents and PARP inhibitors – to the pharmacologic treatments available for ovarian cancer has improved patient outcomes while increasing the available options for the traditionally difficult-to-treat disease."

"The aim of the study is to explore the relationship between CCDC69 expression and resistance of ovarian cancer cells to cisplatin and reveal the underlying mechanism."

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures 

"Comparative analysis revealed CRS/HIPEC to be safe, often safer across the spectrum of NSQIP safety metrics when compared with similar-risk oncologic procedures. Patient selection was important in achieving observed outcomes. High complication rates are a misperception from early CRS/HIPEC experience and should no longer deter referral of patients to experienced centers or impede clinical trial development in the United States."

Risk of Malignant Ovarian Cancer Based on Ultrasonography Findings in a Large Unselected Population 

"According to this study, the ultrasonographic appearance of ovarian masses is strongly associated with a woman’s risk of ovarian cancer. Simple cysts are not associated with an increased risk of ovarian cancer, whereas complex cysts or solid masses are associated with a significantly increased risk of ovarian cancer."  

Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.

https://www.ncbi.nlm.nih.gov/pubmed/30683677/
"Our study suggests that age at diagnosis, family history of breast and/or ovarian cancer, medical history of breast cancer or a Manchester BRCA Score of ≥15 points are associated with a >10% prevalence of germline pathogenic BRCA1/2 variants in epithelial ovarian cancer.

 

 

Studies Seek to Expand on PARP Inhibitor Success in Ovarian Cancer 


Where Does Immune Checkpoint Inhibition Fit in Ovarian Cancer Treatment?



If you run across any interesting articles about ovarian cancer research please share them in the comments below or sent them to me in an e-mail.  I will be sure to add them to this page.  Knowledge is Power. (LiveSTRONG)

Dee
Every Day is a Blessing!
 

Tuesday, August 18, 2015

MedX 2014 : A Year Later


Last year, I had the privilege of attending the Stanford MedX Conference as an e-patient and IDEO Challenge participant. I wrote two posts about that experience here on my blog (MedX - A Place for Conversations  , Design Thinking and Health Care- My MedX IDEO Challenge Experience)

While other e-patients prepare for the MedX Conference this year I started to reflect back on my experience and what impact it has made on my role as an e-patient and cancer advocate.

Connections With Other E-patients
I met Janet Freeman-Daily for the first time at MedX. Janet, a metastatic lung cancer patient, and one of the best lung cancer advocates I know.  After the conference Janet and I continued to interact via Twitter and e-mail. In June, at the ASCO Annual Meeting in Chicago I joined her and a few other lung cancer advocates for dinner. Other ovarian cancer advocates might want to limit their interacts with only other ovarian cancer advocates but I have found that interacting with other cancer advocates from MedX like Janet and  Marie Ennis-O’Connor allows me to be an empathetic well-rounded cancer advocate. It helps to understand the latest treatments for other cancers as the treatments are becoming more mutation based than organ based.

While at MedX I didn’t just develop friendships with other e-patients who were cancer survivors . I learned what is was like to live with rheumatoid arthritis from Annette McKinnon, the importance of patient safety from Meredith Hurston (my roommate), the difficulties patients with prosthesis experience from Joe Riffe and our rights as patients to use and analyze our own data from diabetes e-patient,  Doug Kanter.

Putting It Into Practice
I read two books and a number of articles on design thinking in preparation to the MedX IDEO challenge. (Thanks Dennis Boyle.) But actually putting that type of thinking into practice at the conference was invaluable. I loved working in a team to come up with a solution to my problem: How Might We help cancer survivors understand what to expect after treatment ends?

To this day I find myself putting design thinking into practice as the co-moderator of the #gyncsm community / chat. I have even used it when discussing problems and their solutions in the 55 + community I belong to. When I read health articles online I wonder if the authors asked the patients/survivors what information would be important to them. I actually asked a question along those lines at an ASCO Annual Meeting session on integrating survivorship care plan information into electronic medical records. By the way , the researchers said they had not asked the patients what information was important to them. I suggested they may want to ask them in future studies.

I hope that all the e-patients who attend this year’s Med X conference will not only share their stories with others but will be open to the stories of the other conference attendees. Those stories may move you to tears or make you laugh but I assure you they will make an impact on your life. Oh and don't forget to take Zoey for a walk!

Dee
Every Day is a Blessing!